EICHORCondition: Healthy Volunteers · Sponsor: Alnylam Pharmaceuticals
Interested? Contact the study team ↓
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
This description comes directly from the study's public registry record.
Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2 * Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN) * Has total bilirubin \>ULN * Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg * Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening * Has received an investigational agent within the last 30 days or 5 half-lives
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Clinical Trial Site | London, United Kingdom | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07295717